Import ban extended as India's Pan Pharma racks up third FDA warning letter

Pill packet

The FDA posted another warning letter to Pan Pharmaceuticals that further extends an import alert issued last year, effectively keeping in place a ban on the drugmaker’s products in the U.S.

In the latest warning letter to Pan issued Aug. 25, 2016, the regulatory agency reiterated its concerns with the drugmaker’s Vadodara facility that were uncovered during an inspection in Nov.-Dec. 2015, as well as with the company’s response to previous warnings.

Pan was slapped with a warning letter about conditions at the plant last year and prior to that in 2012 for failing to register with the agency.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

Pan, which is based in Gujarat, India, appears to be climbing to the top of a long list of Indian drugmakers the FDA has found to have substandard manufacturing processes.

Inspectors touring the site late last year cited Pan for disrepair, including rusty production equipment, contaminants near the manufacturing area, including mold, and building infrastructure that allowed pigeons and lizards into the production area. 

FDA inspectors also found rodent droppings within three feet of bags said to contain drug product. When confronted by inspectors about the conditions, a Pan spokesman “told our investigator that your firm had no cleaning procedure for the equipment or facility,” the FDA said in the warning letter.

The agency also came down hard on Pan for its poor record-keeping and quality-control systems at the facility.

Indian drugmakers account for a large portion of the generic and OTC medications that U.S. consumers use, about 40%, but the Indian industry also accounts for many of the warning letters and plant bans that the FDA issues. In a survey by Reuters last year, 42 Indian manufacturing facilities were banned from shipping products into the U.S., while 40 facilities in China were on the import ban list.

- here’s the latest FDA warning letter

Related Article:
FDA issues import alert on Pan Pharma, ramping up its pressure on the India drugmaker

Read more on

Suggested Articles

Three Samsung execs face up to two years in jail for their roles in destroying data and documents at under-fire affiliate Samsung BioLogics.

The FDA has slapped a U.S. drug repackager, saying in a warning letter that its storage processes and equipment cleaning are not up to expectations.

Higher operating costs were behind a 17% slide in pretax profits last year at Allergan’s Mayo, Ireland, facility that produces Botox.